RxDoctor Payments Data

Steven Minaglia, MD

Urogynecology and Reconstructive Pelvic Surgery · Honolulu, HINPI 1528116514

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,281 of the $3,663 with a category attached, or 62.3%. 13 manufacturers reported payments, led by Intuitive Surgical at 41.7% of the total. 2025 is the largest year on record at $2,090, more than ten times the $141 reported in 2019.

$3,663in general payments, 2019–2025

Across 49 payments — averaging $74.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Medtronic$1K
  • Axonics, Inc.$465
  • AbbVie$209
  • Hologic Sales And Service, LLC$141
  • Amgen$66
  • plus $185 from 7 others

What the payments were for

  • Travel & lodging$63117%
  • Food & beverage$2,28162%
  • Education$75020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$136,673
Medicare patients
267
Services billed
2,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron73$83,360
GemtesaVibegron57$65,929
Estradiol296$20,856
BotoxOnabotulinumtoxina20$13,018
YuvafemEstradiol54$10,570
PremarinEstrogens, Conjugated19$8,017
Solifenacin Succinate106$6,626
NitrofurantoinNitrofurantoin Macrocrystal45$3,786
Methenamine Hippurate24$2,691
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst92$1,267
Tolterodine Tartrate ErTolterodine Tartrate18$1,096
Cephalexin53$706
Oxybutynin Chloride ErOxybutynin Chloride28$606
Hydroxyzine Hcl32$574
Oxybutynin Chloride13$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$22$83,36073 claims
Sumitomo Pharma America, Inc.Gemtesa$40$65,92957 claims
AbbVieBotox$209$13,01820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →